Results 251 to 260 of about 9,263,948 (394)

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Tumor-associated macrophages: potential role in skeletal involvement in classic Hodgkin lymphoma. [PDF]

J Pathol Clin Res
Andersen MD, Wolter K, Enemark MH, Pedersen MA, Gormsen LC, Lauridsen KL, Starklint J, Hamilton-Dutoit SJ, d'Amore F, Ludvigsen M, Kamper P.   +10 more
europepmc   +1 more source

Creating the Basis for a Breast Health Program for Female Survivors of Hodgkin Disease Using a Participatory Research Approach [PDF]

, 2005
Deborah B. Crom, Pamela S. Hinds, Jami S. Gattuso, Vida L. Tyc, Melissa M. Hudson   +4 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access. [PDF]

Sci Rep
Suttantapidok S, Kungwankiattichai S, Owattanapanich W.   +2 more
europepmc   +1 more source

Hodgkin and Reed–Sternberg cells express functional c‐kit receptors and interact with primary fibroblasts from Hodgkin's disease‐involved lymph nodes through soluble and membrane‐bound stem cell factor

, 2002
Donatella Aldinucci, Dalisa Poletto, Paola Nanni, Massimo Degan, Annunziata Gloghini, Raffaele Di Francia, Stefania Russo, Antonino Carbone, Antonio Pinto, Valter Gattei   +9 more
openalex   +1 more source

Ifosfamide, Idarubicin, and Etoposide in Relapsed/Refractory Hodgkin Disease or Non-Hodgkin Lymphoma: A Salvage Regimen with High Response Rates before Autologous Stem Cell Transplantation [PDF]

, 2005
Başak Oyan, Yener Koç, Evren Özdemir, Ayşe Kars, Alev Türker, Gülten Tekuzman, Emin Kansu   +6 more
openalex   +1 more source

Nucleolar Organization in Response to Transcriptional Stress

Cancer Science, EarlyView.
In this review, we provide an overview of the research field on nucleolar regulation, mainly focusing on nucleolar organization under transcriptional stress. We also highlight the importance of ribosomal DNA stability, particularly in disease prevention, including cancer.
Rikiya Imamura, Takaaki Yasuhara
wiley   +1 more source

Comparative global burden analysis of lymphoma subtypes: a statistical evaluation of severity across global regions. [PDF]

Front Public Health
Liang Y, Tang Y, WanYan Y, Li E.
europepmc   +1 more source

795. The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes for the Treatment of Relapsed EBV +ve Hodgkin Disease and Non-Hodgkin Lymphoma [PDF]

, 2005
Catherine M. Bollard, Stephen Gottschalk, Elizabeth L. Buza, Helen Huls, Vicky Gresik, George Carrum, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop   +8 more
openalex   +1 more source